Emerging Mycobacteria spp. in Cooling Towers

To the Editor: The importance of nontuberculous mycobacteria (NTM) in various clinical situations recently has increased. Members of the Mycobacterium avium complex (MAC) cause a high percentage of infections in persons with acquired immunodeficiency syndrome. Some species are considered emerging pathogens, particularly those of the M. chelonae–M. abscessus group. They occur not only in immunocompromised persons but also in persons without predisposing conditions. Although sources of infection are considered to originate from the human environment, until now cooling towers were not clearly demonstrated to be one of these contamination sources, despite being suspected (1). Natural streams, ground-

water, brook waters, and swamps already were reported to contain different species of NTM. Constructed environments, such as hospital hot water systems, aerosols from showers, ice machines, swimming pools, dental unit water, endoscopes, and bronchoscopes are other sources (2). Other studies have shown members of MAC in drinking-water distribution systems (3).

A 1999 study in South Africa reported the presence of mycobacteria in cooling towers but reported no details about species (4). In 2003, cooling towers were reported to be a potential source of slow-growing mycobacterial species (1). Some mycobacterial species recently were shown to survive within amebae (5). We aimed to study the population of ameba-associated mycobacterial species in 3 cooling towers using a co-coculture method.

These cooling towers (E, H, and O), located in downtown Paris, France, were sampled in May 2006. Water was taken in a sample point of the cooling circuit located just before the entrance of the tower basins. Because these cooling towers are regularly treated by oxidizing biocide BCDMH (1-bromo-3-chloro-5, 5-dimethylhydantoin) to prevent development of Legionella spp., no Legionella spp. or Legionella-like amebal pathogens were isolated.

Two liters of water samples were filtered through 0.22-μm pore-sized filters that were injected onto amebal microplates as previously described (6) and incubated at 32°C. We screened amebal microplates by examination under inverted microscope and by Ziehl-Nielsen, Gram, and Gimenez staining. Positive wells were subcultured on axenic medium and incubated at 32°C for 10 days. Acid-fast isolates were identified by using partial rpoB gene amplification and sequencing with Myco-F and Myco-R primers (7). These primers did not allow amplification of partial rpoB gene for the 6 M. phocaicum strains. We thus used Myco-F/Myco-Rbon (5′-AGCGGCTGCTGGGTGATCAT-3′) primer pair for M. phocaicum (8). We compared these sequences with the rpoB gene sequence of Mycobacterium type strains available in the GenBank database by using BLASTn on the NCBI website (www.ncbi.nlm.nih.gov).

We observed bacteria growing in amebae. Subculture on axenic media led to polymicrobial cultures and allowed isolation of 33 mycobacterial strains (Table). All these strains were submitted to molecular identification. The 33 isolates corresponded to 5 mycobacterial species: M. fortuitum, M. conceptionense, M. chelonae, M. chimaera, and M. phocaicum (Table). Some of these mycobacteria already had been shown to survive in free-living amebae and to be implicated in human diseases, such as M. chelonae (5). The same author demonstrated recently that 26 environmental mycobacteria survived in the trophozoites and cysts of Acanthamoeba polyphaga (5). The recently described species M. phocaicum was isolated only in samples from humans and was associated with chronic pneumonia (9). However, the natural source of this species is still unknown. M. fortuitum was described as an opportunistic Mycobacterium associated with disseminated infections in a leukemia patient or in furunculosis after footbath in nail

| Closest officially described species (rpoB) | Isolates (no.), N = 33 | Range in % gene similarity to type strain (GenBank accession no.) | Accession numbers of sequences of isolates |
|---------------------------------------------|------------------------|---------------------------------------------------------------|------------------------------------------|
| Mycobacterium chelonae                       | O (2), E (2)           | 99.7 (AY147163)                                             | EU770577                                 |
| M. conceptionense                            | O (12)                 | 99.2–99.9 (AY859695)                                        | EU770583, EU770584                       |
| M. fortuitum                                 | E (2), H (5), O (3)    | 99.5–99.7 (AY147165)                                        | EU770578, EU770579, EU770580             |
| M. chimaera                                  | H (1)                  | 99.7 (EF521908)                                              | EU770576                                 |
| M. phocaicum                                 | E (5), O (1)           | 98.3–98.6 (AY859693)                                        | EU770581, EU770582                       |
salons. *M. conceptionense* belongs to the *M. fortuitum* group and was isolated in a posttraumatic osteitis inflammation (10). *M. chimaera* belongs to MAC and has been isolated only in patients with pulmonary disorders but not from immunocompromised patients. The authors reported that the isolate showed unusually high virulence. We isolated this species for the first time in an environmental sample. It could belong to the transitory flora of the H cooling tower because it was isolated only once in our samples. Cooling towers already had been investigated for slow-growing mycobacteria (1), and our study showed they also can be an environmental source of rapidly growing NTM pathogens. In our procedure for amebal co-cultures, incubation cannot last >10 days because amebae do not survive longer in Page's amebal saline buffer. Moreover, agar plates were incubated for 10 days only, which explains why we could recover only rapidly growing mycobacteria. The cooling towers, already known as a source of dissemination of *Legionella* spp., may disseminate mycobacteria in aerosols and be a previously nonrecognized source of infection.

Isabelle Pagnier,
Michèle Merchat, Didier Raoult, and Bernard La Scola

Author affiliations: Unité des Rickettsies, Marseille, France (I. Pagnier, D. Raoult, B. La Scola); and Climespace Service Recherche & Développement, Paris, France (M. Merchat)

DOI: 10.3201/eid1501.071356

References

1. Black WC, Berk SG. Cooling towers—a potential environmental source of slow-growing mycobacterial species. AJHA J (Fairfax, Va). 2003;64:238–42. DOI: 10.1080/1542811030898413

2. Thomas V, Herrera-Rimann K, Blanc DS, Greub G. Biodiversity of amoebe and amoeba-resisting bacteria in a hospital water network. Appl Environ Microbiol. 2006;72:2428–38. DOI: 10.1128/AEM.72.4.2428-2438.2006

3. Aronson T, Holtzman A, Glover N, Boian M, Froman S, Berlin OG, et al. Comparison of large restriction fragments of *Mycobacterium avium* isolates recovered from AIDS and non-AIDS patients with those of isolates from potable water. J Clin Microbiol. 1999;37:1008–12.

4. MacDonald R, Smit E, Lowne-Hughes S, Rammanner P, Brozel VS. 16S rDNA sequence analysis of a bacterial biofilm community in an industrial cooling water system. In: Abstracts of the 99th General Meeting of the American Society for Microbiology; Chicago, IL; 1999 May 30–June 3. Washington: American Society for Microbiology; 1999. Abstract N-156.

5. Adekambi T, Ben SS, Khilif M, Raoult D, Drancourt M. Survival of environmental mycobacteria in *Acanthamoeba polyphaga*. Appl Environ Microbiol. 2006;72:5974–81. DOI: 10.1128/AEM.03075-05

6. La Scola B, Barrassi L, Raoult D. Isolation of new fastidious alpha *Proteobacteria* and *Afipia felis* from hospital water supplies by direct plating and amoebal co-culture procedures. FEMS Microbiol Ecol. 2000;34:129–37.

7. Adekambi T, Colson P, Drancourt M. *rpoB*-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. J Clin Microbiol. 2003;41:5699–708. DOI: 10.1128/JCM.41.12.5699–5708.2003

8. Kim BJ, Lee SH, Lyu MA, Kim SJ, Bai GH, Chae GT, et al. Identification of mycobacterial species by comparative sequence analysis of the RNA polymerase gene (*rpoB*). J Clin Microbiol. 1999;37:1714–20.

9. Adekambi T, Berger P, Raoult D, Drancourt M. *rpoB* gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of *Mycobacterium bolletii* sp. nov., *Mycobacterium phocaicum* sp. nov. and *Mycobacterium avibacterium* sp. nov. Int J Syst Evol Microbiol. 2006;56:133–43. DOI: 10.1099/ijs.0.63969-0

10. Adékambi T, Stein A, Carvajal J, Raoult D, Drancourt M. Description of *Mycobacterium conceptionense* sp. nov., a *Mycobacterium fortuitum* group organism isolated from a posttraumatic osteitis inflammation. J Clin Microbiol. 2006;44:1268–73. DOI: 10.1128/JCM.44.4.1268-1273.2006

Address for correspondence. Bernard La Scola, Unité des Rickettsies, CNRS UMR 6020, Faculté de Médecine de Marseille, 27 Blvd Jean Moulin, 13385 Marseille CEDEX 05, France; email: bernard.lascola@univmed.fr

**Clostridium difficile**-related Hospitalizations among US Adults, 2006

To the Editor: The threat to public health posed by *Clostridium difficile*-associated disease (CDAD) continues to increase within and outside the United States. In a recent analysis, we detected a 23% annual increase in CDAD-related hospitalizations from 2000 through 2005 and a near-doubling in the associated age-adjusted case-fatality rate from 2000 through 2004 (1). In view of the aging US population, this rapid growth, along with the increased virulence and diminished susceptibility to antimicrobial drug treatments, if sustained, will not only strain the US healthcare system (2,3) but also will cause significant illness and death. For this reason, understanding up-to-date trends in CDAD-related hospitalizations is critical. Since the Agency for Healthcare Research and Quality recently made available its 2006 update to the National Inpatient Sample (NIS) data (4) on the Healthcare Costs and Utilization Project Net (HCUPNet) website (5), I explored the trends in CDAD hospitalizations beyond our 2005 estimates.

From the HCUPNet website (5), I identified CDAD-related hospitalizations for 2000–2006 in the NIS data (4). The NIS is a stratified 20% sample of US community hospitals, and data are weighted to provide national estimates (4). CDAD was identified by presence of the International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) diagnosis code 8.45 (intestinal infection with *Clostridium difficile*), and the numbers of discharges per year were age-stratified. To benchmark CDAD incidence against the general growth in hospitalizations over time, I obtained age-stratified numbers of total hospitalizations from HCUPNet.